(Q47917780)

6 February 2018

title

DNase in stable cystic fibrosis infants: a pilot study (English)

1 reference

6 February 2018

0 references

6

Johan C de Jongste

1 reference

6 February 2018

author name string

Maartje Ten Berge

1

1 reference

6 February 2018

Els van der Wiel

2

1 reference

6 February 2018

Harm A W M Tiddens

3

1 reference

6 February 2018

Peter J F M Merkus

4

1 reference

6 February 2018

Wim C J Hop

5

1 reference

6 February 2018

publication date

1 December 2003

1 reference

6 February 2018

Journal of Cystic Fibrosis

published in

1 reference

6 February 2018

volume

2

1 reference

6 February 2018

issue

4

1 reference

6 February 2018

page(s)

183-188

1 reference

6 February 2018

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

1 reference

7 January 2021

Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Dose-dependent in vitro effect of recombinant human DNase on rheological and transport properties of cystic fibrosis respiratory mucus

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Efficacy and safety of short-term administration of aerosolised recombinant human DNase I in adults with stable stage cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Medium term treatment of stable stage cystic fibrosis with recombinant human DNase I.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Effects of 12-week administration of dornase alfa in patients with advanced cystic fibrosis lung disease. Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. The Pulmozyme Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Bronchial mucous glands in the newborn with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

The lung in cystic fibrosis. A quantitative study including prevalence of pathologic findings among different age groups

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Early bacteriologic, immunologic, and clinical courses of young infants with cystic fibrosis identified by neonatal screening

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Lower respiratory infection and inflammation in infants with newly diagnosed cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Increased DNA levels in bronchoalveolar lavage fluid obtained from infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Early pulmonary infection, inflammation, and clinical outcomes in infants with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Cystic fibrosis: CT assessment of lung involvement in children and adults

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Plethysmographic measurements of lung volume and airway resistance. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/ American Thoracic Society.

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Tidal forced expirations. ERS/ATS Task Force on Standards for Infant Respiratory Function Testing. European Respiratory Society/American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Standards and indications for cardiopulmonary sleep studies in children. American Thoracic Society

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Normal polysomnographic values for children and adolescents

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Bronchodilator responsiveness in infants and young children with cystic fibrosis

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Pulmonary function in infants with cystic fibrosis: the effect of antibiotic treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Clinical studies of rhDNase in moderately and severely affected patients with cystic fibrosis--an overview

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Lung function testing in infants with cystic fibrosis: lessons from the past and future directions

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

Use of computerized tomography and chest x-rays in evaluating efficacy of aerosolized recombinant human DNase in cystic fibrosis patients younger than age 5 years: a preliminary study

1 reference

https://api.crossref.org/works/10.1016%2FS1569-1993%2803%2900090-0

7 January 2021

10.1016/S1569-1993(03)00090-0

Identifiers

DOI

1 reference

6 February 2018

1 reference

6 February 2018